Latest news

• Roche sets disruptive price for new MS drug Ocrevus in US

  remitting form, where Ocrevus' twice-yearly dosing gives it an advantage over other injectable MS therapies such as Biogen's Tysabri (natalizumab) and Zinbryta (daclizumab).

• NICE backtracks on Biogen's multiple sclerosis drug Zinbryta

  NICE turned down Zinbryta in draft guidance issued last October, criticising the analysis submitted by Biogen of the cost effectiveness of daclizumab compared with other disease-modifying treatments. ... Zinbryta is also being considered for use by the

• Biogen elevates Vounatsos to top seat

  recently-approved Zinbryta (daclizumab) and bringing forward phase III Alzheimer's disease candidate aducanumab.

• Biogen's CEO Scangos to step down

  Vounatsos highlighted the prospects for just-approved Zinbryta (daclizumab), a once-monthly MS therapy which is due for launch in the US and Germany next month, as well as the

• Roche's MS drug Ocrevus awarded priority review by FDA

  If approved Ocrevus will compete for MS market share with Biogen's recently-approved Zinbryta, while Novartis has an anti-B cell candidate in its pipeline, which the company claims has